About this trial
The goal of this multicenter, double-blind, randomized controlled trial is to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) stellate ganglion modulation for improving autonomic function and sleep quality in perioperative cardiovascular disease patients.
The main questions it aims to answer are:
1. Does LIFU improve heart rate variability and sleep characteristics from baseline at 3-7 days post-surgery compared to sham ultrasound? 2. Does LIFU improve serological markers, vital signs, Pittsburgh Sleep Quality Index (PSQI), and reduce \>30-second perioperative arrhythmias? 3. What is the safety profile of LIFU in this population? 200 eligible patients will be randomized 1:1 to receive either active LIFU (2.0W, 1MHz, 50% duty cycle, 30min daily for 3-7 days) plus standard care, or identical sham ultrasound plus standard care. A four-party double-blind design (subjects, operators, assessors, analysts) will be implemented. The study will run from May 1, 2026 to April 1, 2027 at 6 centers in China.
Participants will:
1. Complete pre-surgery screening and baseline assessments (PSQI, 12h ECG/sleep monitoring, residual blood sample collection) 2. Receive daily assigned ultrasound intervention for 3-7 consecutive days post-surgery 3. Undergo 72h continuous ECG monitoring post-surgery, and repeat assessments at 3-7 days 4. Have all adverse events and arrhythmias recorded throughout the study 5. May withdraw voluntarily at any time without affecting routine medical care
Eligibility criteria
Qualifiers
Diagnosed with cardiovascular disease (CVD) and scheduled to undergo cardiology-related surgical treatment
Able to receive and tolerate the aforementioned cardiology-related surgical treatment
Aged between 18 and 79 years (inclusive), with no restriction on gender
Agree to accept random allocation of the treatment strategies
Disqualifiers
Have used sedative-hypnotic drugs, antipsychotic drugs, opioid analgesics, antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), central nervous system (CNS) stimulant drugs, or any other medications that alter sleep architecture within the past 30 days
Have a history of cervical infection, trauma, severe cervical deformity, or prior cervical surgery
Unable to complete the daily study intervention as required by the trial protocol
Are participating in another clinical trial, or have participated in other clinical trials with interventions that may interfere with the results of this study
Trial design
Treatments tested in this trial
- Low-intensity focused ultrasound (LIFU) targeting the left stellate ganglion
- Sham low-intensity focused ultrasound targeting the left stellate ganglion
Treatment groups
Sponsors and collaborators
Renmin Hospital of Wuhan University
Lead sponsor
Yichang Central People's Hospital
Collaborator
Wuhan Central Hospital
Collaborator
Huangshi Central Hospital
Collaborator
Wuhan Third Hospital
Collaborator
Xiangyang Central Hospital
Collaborator
Jingzhou Central Hospital
Collaborator